Hennion & Walsh Asset Management Inc. Takes $1.41 Million Position in ARS Pharmaceuticals, Inc. $SPRY

Hennion & Walsh Asset Management Inc. purchased a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 175,614 shares of the company’s stock, valued at approximately $1,407,000.

Other hedge funds also recently added to or reduced their stakes in the company. Rubric Capital Management LP lifted its position in ARS Pharmaceuticals by 247.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,500,000 shares of the company’s stock valued at $45,225,000 after acquiring an additional 3,205,122 shares in the last quarter. Millennium Management LLC bought a new stake in shares of ARS Pharmaceuticals in the 4th quarter worth $36,912,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of ARS Pharmaceuticals in the 2nd quarter worth $30,154,000. UBS Group AG raised its stake in shares of ARS Pharmaceuticals by 235.0% in the fourth quarter. UBS Group AG now owns 2,210,866 shares of the company’s stock worth $25,757,000 after purchasing an additional 1,550,980 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in shares of ARS Pharmaceuticals in the third quarter worth $10,400,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, insider Eric Karas sold 25,000 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $250,000.00. Following the transaction, the insider owned 12,176 shares of the company’s stock, valued at approximately $121,760. This represents a 67.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alexander A. Fitzpatrick sold 3,355 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $33,550.00. Following the completion of the transaction, the insider directly owned 90,910 shares in the company, valued at $909,100. The trade was a 3.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 33.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on SPRY shares. Wall Street Zen raised ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings raised ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. Cantor Fitzgerald upped their target price on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 28th. Finally, Leerink Partners dropped their price target on shares of ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Thursday, June 25th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $28.20.

ARS Pharmaceuticals Price Performance

Shares of SPRY opened at $6.05 on Thursday. The firm has a fifty day simple moving average of $7.69 and a two-hundred day simple moving average of $8.35. The firm has a market cap of $600.78 million, a PE ratio of -3.01 and a beta of 0.98. The company has a current ratio of 4.94, a quick ratio of 4.77 and a debt-to-equity ratio of 2.79. ARS Pharmaceuticals, Inc. has a 1-year low of $4.91 and a 1-year high of $16.65.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative return on equity of 153.61% and a negative net margin of 200.00%.The firm had revenue of $22.68 million during the quarter, compared to analysts’ expectations of $22.20 million. On average, equities analysts anticipate that ARS Pharmaceuticals, Inc. will post -1.95 EPS for the current year.

ARS Pharmaceuticals News Summary

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Negative Sentiment: Levi & Korsinsky said the lawsuit alleges ARS Pharmaceuticals did not adequately disclose that CVS Caremark’s rigid formulary system could delay a neffy coverage decision until January 2027, potentially causing the product to miss the summer and back-to-school allergy seasons. Levi & Korsinsky lawsuit notice
• Negative Sentiment: Several firms, including Rosen, Kaplan Fox, Faruqi & Faruqi, Pomerantz, and Bronstein Gewirtz & Grossman, announced or promoted the filed securities class action covering investors who purchased ARS securities from March 9 through June 24, 2026. The allegations could increase legal costs, reputational pressure, and uncertainty around neffy’s commercial outlook. Rosen class action announcement Kaplan Fox class action notice
• Neutral Sentiment: October 5, 2026 is the deadline for investors to seek appointment as lead plaintiff. The notices are largely attorney solicitations and do not represent a court finding that ARS Pharmaceuticals violated securities laws; the company’s potential liability remains unresolved. Faruqi class action deadline
• Neutral Sentiment: A reported short-interest update showed zero shares and a zero-day days-to-cover ratio, but the figures appear anomalous and provide little useful evidence about investor positioning.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.